Mostafa Kamal to Become Prime Therapeutics’ New President and CEO
Executive succeeds Ken Paulus as head of the PBM.
Prime Therapeutics LLC, a pharmacy benefit manager (PBM), revealed that Mostafa Kamal will succeed Ken Paulus as its president and CEO. Kamal currently serves as president of the PBM, and the CEO of Magellan Rx, a Prime Therapeutics company.
During his tenure as Magellan Rx’s CEO, Kamal led the company through a period of growth, transformation, and diversification, which the business says provided Magellan Rx with a boost in the specialty drug management, state government pharmacy solutions, and middle market pharmacy benefit management solutions spaces.
"Mostafa's vision for what we can become is inspiring and bold," notes Maurice Smith, Prime's board chairman and president, CEO and vice chair of Health Care Service Corporation (HCSC). "As Prime seeks to reimagine pharmacy benefit management, he is the right person to build on the strong foundation Ken leaves as he retires."
Strategic Trends in Pharmaceutical Manufacturing for Industry Leaders
March 10th 2025This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.
